Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1965 1
1966 19
1967 47
1968 61
1969 82
1970 86
1971 108
1972 88
1973 120
1974 138
1975 112
1976 99
1977 99
1978 97
1979 124
1980 104
1981 125
1982 114
1983 125
1984 140
1985 180
1986 137
1987 236
1988 186
1989 307
1990 295
1991 238
1992 285
1993 282
1994 271
1995 275
1996 247
1997 241
1998 217
1999 237
2000 246
2001 244
2002 235
2003 262
2004 261
2005 308
2006 319
2007 384
2008 512
2009 503
2010 593
2011 627
2012 717
2013 769
2014 798
2015 795
2016 716
2017 758
2018 753
2019 373
2020 13
Text availability
Article attribute
Article type
Publication date

Search Results

14,359 results
Results by year
Filters applied: . Clear all
Page 1
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance.
Grimwade D, et al. Blood 2016 - Review. PMID 26660431 Free PMC article.
Recent major advances in understanding the molecular basis of acute myeloid leukemia (AML) provide a double-edged sword. Although defining the topology and key features of the molecular landscape are fundamental to development of novel treatment approaches and provide opportunities for greater individualization of therapy, confirmation of the genetic complexity presents a huge challenge to successful translation into routine clinical practice. ...The reward of identifying AML-defining molecular lesions present in all leukemic populations (including subclones) has been exemplified by acute promyelocytic leukemia, where successful targeting of the underlying PML-RARα oncoprotein has eliminated the need for chemotherapy for disease cure. ...
Recent major advances in understanding the molecular basis of acute myeloid leukemia (AML) provide a double-edged sword …
Emerging therapies for acute myeloid leukemia.
Saygin C and Carraway HE. J Hematol Oncol 2017 - Review. PMID 28420416 Free PMC article.
Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity. Despite the advances in our understanding of its pathobiology, the chemotherapy-directed management has remained largely unchanged in the past 40 years. ...The classes of agents described in this review include novel cytotoxic chemotherapies (CPX-351 and vosaroxin), epigenetic modifiers (guadecitabine, IDH inhibitors, histone deacetylase (HDAC) inhibitors, bromodomain and extraterminal (BET) inhibitors), FMS-like tyrosine kinase receptor 3 (FLT3) inhibitors, and antibody-drug conjugates (vadastuximab), as well as cell cycle inhibitors (volasertib), B-cell lymphoma 2 (BCL-2) inhibitors, and aminopeptidase inhibitors. ...
Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity. Despite the advances in our und
[II.Acute Myeloid Leukemia].
Asou N. Gan To Kagaku Ryoho 2017. PMID 28536333 Japanese.
Recent advances in the understanding and treatment of acute myeloid leukemia.
Watts J and Nimer S. F1000Res 2018 - Review. PMID 30135719 Free PMC article.
Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that has a poor prognosis. Recent advances in genomics and molecular biology have led to a greatly improved understanding of the disease. ...Here, we review novel drug targets in AML with a focus on epigenetic-targeted therapies in pre-clinical and clinical development as well as the recent new drug approvals....
Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that has a poor prognosis. Recent ad
Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.
Ragon BK and DiNardo CD. Curr Hematol Malig Rep 2017 - Review. PMID 29064021
In this review, the landscape and progress of targeted therapeutics aimed at IDH mutations in AML and related myeloid malignancies will be described. ...The use of IDH targeted therapy is expected to soon become part of a genomically defined and individualized AML treatment strategy....
In this review, the landscape and progress of targeted therapeutics aimed at IDH mutations in AML and related myeloid malignancies wi …
Incorporating newer agents in the treatment of acute myeloid leukemia.
Raj RV, et al. Leuk Res 2018 - Review. PMID 30401522
Despite multiple clinical trials across several decades, little improvement for the therapy of non-APL AML was noted. However, over the last couple of years, several new therapies have demonstrated efficacy in the therapy of patients with AML. Several of those have been approved by the FDA for AML therapy. These include CPX-351, midostaurin, gemtuzumab ozogamicin, enasidenib and ivosidenib. ...
Despite multiple clinical trials across several decades, little improvement for the therapy of non-APL AML was noted. However, over t …
[Advances in targeted therapy for childhood acute myeloid leukemia].
Wang NN and Ye QD. Zhongguo Dang Dai Er Ke Za Zhi 2017 - Review. PMID 28697841 Chinese. Free article.
At present, acute myeloid leukemia (AML) accounts for about 15%-20% of childhood acute leukemia. Although overall survival rate is increasing with the help of risk stratification, stratification of chemotherapy, and supportive treatment, conventional pharmacotherapy still has a limited clinical effect and certain limitations in improving remission rate in previously untreated patients and reducing recurrence after remission. With the development of precision medicine, the mechanisms of targeted therapy, including abnormal activation of AML-related signaling pathways and epigenetic modification, have been found in recent years. ...
At present, acute myeloid leukemia (AML) accounts for about 15%-20% of childhood acute leukemia. Although …
Precision medicine for acute myeloid leukemia.
Lai C, et al. Expert Rev Hematol 2016. PMID 26514194 Free PMC article.
Acute myeloid leukemia (AML) is a heterogeneous collection of myeloid malignancies with diverse genetic etiology and the potential for intra-patient clonal evolution over time. We discuss here how the precision medicine paradigm might be applied to the care of AML patients by focusing on the potential roles of targeting therapy by patient-specific somatic mutations and aberrant pathways, ex-vivo drug sensitivity and resistance testing, high sensitivity measurements of residual disease burden and biology along with potential clinical trial and regulatory constraints....
Acute myeloid leukemia (AML) is a heterogeneous collection of myeloid malignancies with diverse genetic etiology
Molecular targeting in acute myeloid leukemia.
Lim SH, et al. J Transl Med 2017 - Review. PMID 28851395 Free PMC article.
Acute myeloid leukemia (AML) is a heterogenous disease associated with distinct genetic and molecular abnormalities. Somatic mutations result in dysregulation of intracellular signaling pathways, epigenetics, and apoptosis of the leukemia cells. Understanding the basis for the dysregulated processes provides the platform for the design of novel targeted therapy for AML patients. ...
Acute myeloid leukemia (AML) is a heterogenous disease associated with distinct genetic and molecular abnormalities. So
14,359 results
Jump to page
Feedback